Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C

Soriano V, Benítez-Gutiérrez L, Arias A, et al. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol. 2017;13(9):1015-1022.

Publication Type:

Journal Article

Authors:

Soriano, V; Benítez-Gutiérrez, L; Arias, A; et, al

Source:

Expert Opin Drug Metab Toxicol, Volume 13, Issue 9, p.1015-1022 (2017)

Cited On:

Export Citation:
RIS Format
Top